Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: A multicentre audit

BJU International

Volumn 93, Issue 6, 2004, Pages 725-729

  Winkler, M H ^a,f   Khan, F A ^a   Hoh, I M ^a   Okeke, A A ^b   Sugiono, M ^b   Mcinerney, P ^c   Boustead, G B ^d   Persad, R ^e   Kaisary, A V ^a   Gillatt, D A ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c DERRIFORD HOSPITAL   (United Kingdom)

^d LISTER HOSPITAL   (United Kingdom)

^e BRISTOL ROYAL INFIRMARY   (United Kingdom)

^f NONE   (United Kingdom)

Author keywords

Adenocarcinoma; Outcome; Prostate neoplasm; PSA; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; BIOPSY; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 11144355927     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04715.x     Document Type: Article

References (22)

1. Oliver SE, Donovan JL, Peters TJ et al. Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU Int 2003; 91: 331-6
2. Feneley MR, Gillatt DA, Hehir M, Kirby RS. A review of radical prostatectomy from three centres in the UK. Clinical presentation and outcome. Br J Urol 1996; 78: 911-8
3. Bott SR, Kirby RS. Avoidance and management of positive surgical margins before, during and after radical prostatectomy. Prostate Cancer Prostatic Dis 2002; 5: 252-63
4. Doherty AP, Bower M, Smith GL et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83: 1432-6
5. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-23
6. Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65
7. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-7
8. Herr HW. Quality of life in prostate cancer patients. CA Cancer J Clin Aug 1997; 47: 207-17
9. Fowler FJ Jr, Barry MJ, Lu-Yao G et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare experience 1988-90 (updated June 1993). Urology 1993; 42: 622-9
10. Lu-Yao GL, Albertsen P, Warren J et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology 1999; 54: 301-7
11. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995; 172: 65-72
12. Albertsen PC, Hanley JA, Gleason DF et al. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
13. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-9
14. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-6
15. Litwiller SE, Djavan B, Klopukh BV et al. Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period 1984-94 Dallas Outcomes Research Group for Urological Disorders. Urology 1995; 45: 813-22
16. Moul JW, Wu H, Sun L et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002; 132: 213-9
17. Freedland SJ, Presti JC Jr, Amling CL et al. Time trends in biochemical recurrence after radical prostatectomy, results of the SEARCH database. Urology 2003; 61: 736-41
18. Ung JO, Richie JP, Chen MH et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458-63
19. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 281-6
20. Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-34
21. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin Oct 1999; 49: 282-96
22. Hu JC, Gold KF, Pashos CL et al. Role of surgeon Volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21: 401-5